The California-based health system is expanding its partnership with clinical decision support vendor CancerIQ to integrate risk assessment into the Cerner EHR workflow.
The Australian startup, recently out of stealth mode, is reviving the concept of sequencing analysis by mutagenesis for NGS library preparation.
Standards for interoperability and better cooperation among stakeholders will help unleash the power of genomics in cancer care, says the head of the Biden Cancer Initiative.
Flye and wtdbg2, both released this year, work with Pacific Biosciences and Oxford Nanopore data and can assemble bacterial and more complex genomes.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.
University of Crete spinout Gnosis Data Analysis is adding AI capabilities to Indivumed's IndivuType multi-omics cancer research platform.
The Australian startup emerges from stealth with former Solexa CEO Nick McCooke reprising that role at the firm.
Revolution Medicines had been looking to sell Warp Drive's genomic drug discovery platform and microbial genome database since acquiring them in 2018.
With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
The companies will pair sequencing with genotype-phenotype matching and analytics in pursuit of wider access to precision medicine and faster, more accurate diagnoses.
The two Netherlands-based firms will market their joint offering to pharmaceutical companies and others researching immune system-related diseases.
Following an April hackathon and work from Melbourne Genomics and Fred Hutch, the Broad is about to release a long-awaited AWS version of its Cromwell workflow engine.
The La Jolla, California-based firm plans to use the funds to accelerate research partnerships around its LunaDNA genomic data sharing platform.
The test is designed to determine breast cancer risk by analyzing a number of factors including breast density, breast biopsy history, and a polygenic score.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
The year-old Princess Máxima Center, based in Utrecht, has turned to bioinformatics firm The Hyve to address integration and interoperability issues.
With 10,000 of Mayo's patients now sequenced for 77 genes, a subset of this information is being used to inform care while the bulk of the data is spurring research projects.
The in vitro diagnostic is designed to detect whole gene segments for influenza A and B viruses and can characterize viruses as seasonal or nonseasonal.
The new funding brings the Series B total to £23.3 million for the British clinical decision support technology developer.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.